Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Garca, S., Liz, M., Gmez-Reino, J
There's also a larger question hanging over the Medicare breakthrough: Unless the Trump administration extends or replaces the demonstration program, obesity drug coverage is scheduled to expire at the end of 2027
Remove the patch from its liner
Despite widespread demand, affordability and insurance coverage lag far behind medical efficacy
If youre of a certain vintage, and you were in diet culture as a dieter, as a fat person, as a sociologist observing these thingsthen you might be a little more skeptical of this one, she says